Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

nce they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

        -- our ability to borrow additional amounts under the loan from Bay
           City Capital, which is subject to the discretion of Bay City
           Capital;
        -- our ability to obtain necessary financing in the near term,
           including amounts necessary to repay the loan from Bay City Capital
           by the September 14, 2009 maturity date (or earlier if certain
           repayment acceleration provisions are triggered);
        -- our ability to control our operating expenses;
        -- our ability to comply with covenants included in the loan from Bay
           City Capital;
        -- our ability to maintain the listing of our common stock on NASDAQ;
        -- our failure to timely recruit and enroll patients for the FDG-PET
           clinical trial, as well as any future clinical trial;
        -- our failure to obtain sufficient data from enrolled patients that
           can be used to evaluate VIA-2291, thereby impairing the validity or
           statistical significance of our clinical trials;
        -- our ability to successfully complete our clinical trials of
           VIA-2291 on expected timetables and the outcomes of such clinical
           trials;
        -- complexities in designing and implementing cardiovascular clinical
           trials using histological examinations, measurement of biomarkers,
           medical imaging and atherosclerotic plaque bioassays;
        -- the results of our clinical trials, including without limitation,
           with respect to the safety and efficacy of VIA-2291;
        -- if the results of
'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
(Date:9/30/2014)... 30, 2014 OriginOil Inc. (OTC/QB: OOIL), ... process to clean up large quantities of water, announced ... Eckelberry reported on the launch of the company's CLEAN-FRAC™ ... provided by partner STW Resources . , Immediately ... per day (bpd) and achieved a 99.8% reduction in ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
(Date:9/30/2014)... iLab Solutions announced the results of its ... focuses on core facility operations, growth and utilization as ... , In its 4th year running, a number of ... year-over-year decrease in the percentage of revenue that comes ... the constraints of this trend. When asked, “What are ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3
... RainDance Technologies, Inc., a privately held provider ... disease research, today announced it will be shipping ... and reviewed the company,s opportunities for growth at ... initial application of the company,s RainStorm(TM) microdroplet-based technology ...
... and CEO of Cryo-Cell International and C,elle(SM), Welcomes President ... As the CEO of Cryo-Cell International, the nation,s most ... been an active participant in the stem cell and ... the changes that have taken place over the past ...
... Biotech, an Advanced Instruments company, will introduce its ... which delivers faster cycle times, a touch screen ... and efficiency in microbiology laboratories -- at The ... May, 2009."The introduction of the new Autoplate represents ...
Cached Biology Technology:RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference 2RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference 3Stem Cell Industry Insider Mercedes Walton Discusses President Obama's Stem Cell Executive Order 2Stem Cell Industry Insider Mercedes Walton Discusses President Obama's Stem Cell Executive Order 3Spiral Biotech to Introduce New Autoplate Spiral Plating System at ASM General Meeting in May 2Spiral Biotech to Introduce New Autoplate Spiral Plating System at ASM General Meeting in May 3
(Date:9/30/2014)... --- Do we think of nature as something that we ... need to "preserve?" Or do we think of ourselves as ... of nature, but what about a house? , The ... also reflected in our actions, our speech and in cultural ... the University of Washington, the American Indian Center of Chicago ...
(Date:9/30/2014)... do seedless watermelon, salmon, and strawberries all have in ... two sets of chromosomes and are diploid, these organisms ... sets of chromosomesseedless watermelon and salmon have 3 and ... While this might seem surprising, in fact most ... first discovered over a century ago, but only recently, ...
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded ... to develop an electrode array system that will ... works through unprecedented resolution and scale. , LLNL,s ... support President Obama,s BRAIN (Brain Research through ... effort to revolutionize our understanding of the human ...
Breaking Biology News(10 mins):The cultural side of science communication 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... having a child and attending university may be subconsciously influenced ... a Queen,s University study. "Life expectancy might be driving ... doctoral fellow in the Queen,s math department who has a ... to live, the more time they will invest in education. ...
... drink blood and spread disease such as river blindnesscreating misery ... that the pesky insects can be useful. Don Champagne, ... Environmental Sciences, discovered a way to use the black fly,s ... were published in the journal PLoS One . ...
... nanoparticles to convert laser energy into "plasmonic nanobubbles," researchers ... Cancer Center and Baylor College of Medicine (BCM) are ... directly into cancer cells. In tests on drug-resistant cancer ... nanobubbles was up to 30 times more deadly to ...
Cached Biology News:Black flies may have a purpose after all 2Black flies may have a purpose after all 3'Nanobubbles' plus chemotherapy equals single-cell cancer targeting 2'Nanobubbles' plus chemotherapy equals single-cell cancer targeting 3'Nanobubbles' plus chemotherapy equals single-cell cancer targeting 4
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
... transporter 2 (APT2) (Peptide ... PSF2) (Peptide supply factor ... involved in antigen processing ... Antigen: Recombinant ...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Biology Products: